Cookies help us deliver our services. By using our services, you agree to our use of cookies.
Learn more
OK
Skip to main content (Press Enter).
Sign In
Skip auxiliary navigation (Press Enter).
Contact Us
Skip main navigation (Press Enter).
Toggle navigation
Search Options
About
What is the AMS
AMS International Scientific Committee
AMS Educational Executive Committee
AMS Ambassadors
Certification & Accreditation
Upcoming Events
Videos & Webinars
International Events
Become a Speaker
Videos On Demand
Education 365
Features
AMS Features
Blogs
Industry
Industry Partners
Become a Sponsor
Features
Blogs
Blog Viewer
Blogs
The current treatment landscape in adult atopic dermatitis in the United States: results from a cross-sectional real-world study
By
- AMS
posted
Mar 23, 2021 09:24 AM
0
Recommend
.
0 comments
0 views
Related Content
Systemic treatment of psoriasis and psoriatic arthritis in the United States: a cross-sectional study
- AMS
Added Jul 27, 2020
Blog Entry
Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab – a cross-sectional study from the BioDay registry
- AMS
Added Jun 21, 2021
Blog Entry
Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study
- AMS
Added Feb 09, 2021
Blog Entry
Effectiveness of ustekinumab in patients with atopic dermatitis: analysis of real-world evidence
- AMS
Added Aug 26, 2021
Blog Entry
SkinCeuticals, CeraVe, La Roche-Posay & Melanoma Research Alliance Launch Three-Year Partnership in the United States
- AMS
Added May 04, 2020
Blog Entry
Permalink
© 2022 AMS, Aesthetic Multispecialty Society. All Rights Reserved.
Powered by Higher Logic